NEPTUNE China Cohort: First-Line Durvalumab plus Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

被引：0
|
作者：
Cheng, Y. [1 ]
Zhou, Q. [2 ]
Han, B. [3 ]
Fan, Y. [4 ]
Shan, L. [5 ]
Chang, J. [6 ,7 ]
Sun, S. [7 ]
Fang, J. [8 ]
Chen, Y. [9 ]
Sun, J. [10 ]
Wu, G. [11 ]
Mann, H. [12 ]
Naicker, K. [12 ]
Shire, N. [13 ]
Mok, T. [14 ]
De Castro, G. [15 ]
机构：
[1] Jilin Canc Hosp, Changchun, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Xinjiang Med Univ, Affiliated Canc Hosp, Urumqi, Xinjiang, Peoples R China
[6] Shenzhen Ctr, Chinese Acad Med Sci, Canc Hosp, Shenzhen, Peoples R China
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[10] Army Med Univ, Inst Canc, Xinqiao Hosp, Chongqing, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Union, NJ USA
[12] AstraZeneca, Cambridge, England
[13] AstraZeneca, Gaithersburg, MD USA
[14] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China
[15] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Durvalumab; Tremelimumab; NEPTUNE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-04
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 50 条
  • [1] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    de Castro Jr, Gilberto
    Rizvi, Naiyer A.
    Schmid, Peter
    Syrigos, Konstantinos
    Martin, Claudio
    Yamamoto, Nobuyuki
    Cheng, Ying
    Moiseyenko, Vladimir
    Summers, Yvonne
    Vynnychenko, Ihor
    Lee, Sung Yong
    Bryl, Maciej
    Zer, Alona
    Erman, Mustafa
    Timcheva, Constanta
    Raja, Rajiv
    Naicker, Kirsha
    Scheuring, Urban
    Walker, Jill
    Mann, Helen
    Chand, Vikram
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
  • [2] NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
    Cheng, Ying
    Zhou, Qing
    Han, Baohui
    Fan, Yun
    Shan, Li
    Chang, Jianhua
    Sun, Si
    Fang, Jian
    Chen, Yuan
    Sun, Jianguo
    Wu, Gang
    Mann, Helen
    Naicker, Kirsha
    Shire, Norah
    Mok, Tony
    de Castro Jr, Gilberto
    LUNG CANCER, 2023, 178 : 87 - 95
  • [3] First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
    Mok, Tony
    Schmid, Peter
    De Castro, Gilberto, Jr.
    Syrigos, Kostas
    Martin, Claudio
    Yamamoto, Nobuyuki
    Aren, Osvaldo
    Arrieta, Oscar
    Gottfried, Maya
    Jazieh, Abdul Rahman
    Ramlau, Rodryg
    Timcheva, Constanta
    Trani, Leonardo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1084 - S1084
  • [4] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [5] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
    Thomas, M.
    Grohe, C.
    Eberhardt, W.
    Rawluk, J.
    Reck, M.
    Laack, E.
    Wesseler, C.
    Rittmeyer, A.
    Alt, J.
    Reinmuth, N.
    Griesinger, F.
    Kern, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
  • [6] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Therapy for metastatic NSCLC: Results of the Phase 3 POSEIDON Study
    Rawluk, J.
    Johnson, M. L.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Kim, S. -W
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. -T
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Medic, N.
    Peters, S.
    Garon, E.
    Mok, T. S. K.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 102 - 103
  • [7] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
    Johal, Sukhvinder
    Miranda, Miguel
    Sarbajna, Tina
    Shi, Xiaojin
    Greystoke, Alastair
    Johnson, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
  • [8] Durvalumab (D) plus /- tremelimumab (T) plus chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
    Cho, Byoung Chul
    Reinmuth, Niels
    Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Trukhin, Dmytro
    Kim, Sang-We
    Ursol, Grygorii
    Hussein, Maen A.
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz H.
    Saito, Haruhiro
    Marotti, Miriam
    Barrett, Karen
    Shi, Xiaojin
    Peters, Solange
    Garon, Edward B.
    Mok, Tony S. K.
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [10] Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Martin, C.
    Zhao, L.
    McIntosh, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
12345